In December 2021, Pew’s antibiotic resistance project discontinued its work tracking antibiotics and nontraditional products in global clinical development. The World Health Organization has more information on the state of the global antibiotic pipeline.
Editor's note: On April 5, 2021, this piece was updated to change the drug type of KB109 from “live biotherapeutic product” to “synthetic polymer.”
As of December 2020, an estimated 36 new nontraditional products with the potential to treat or prevent serious bacterial infections were in clinical development.
The below interactive resource—based on publicly available information and informed by external experts and company communication—focuses on the nontraditional products currently in the clinical development pipeline. To view subsets of products, use filter options below or click on corresponding sections of the pie charts.
Please contact [email protected] with additions or updates.
For definitions of drug development terms and nontraditional product types, visit https://www.pewtrusts.org/en/research-and-analysis/articles/2014/03/12/glossary-for-the-antibiotic-pipeline .
See the methodology section for further details.
Note: The following drugs have been removed from the pipeline. Removed candidates will be included in future updates if development resumes:
- June 2019: S. pneumoniae next generation vaccine (GSK-2189241A) was discontinued, according to a press release from the company.
- December 2018: SA4Ag was removed because development was discontinued, according to a press release from the company.
- June 2018: ASN100, GEN 004, Group B Streptococcus vaccine, and VLA84 (IC84) were removed because they were no longer included in the research and development pipeline on the company’s website.
- September 2017: Shigamab and Cdiffense were removed because they were no longer included in the research and development pipeline on the company’s website.
America’s Overdose Crisis
Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care